<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01687491</url>
  </required_header>
  <id_info>
    <org_study_id>AXA_2012</org_study_id>
    <nct_id>NCT01687491</nct_id>
  </id_info>
  <brief_title>Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome</brief_title>
  <acronym>AXA</acronym>
  <official_title>Comparison of Anti-Xa Activity in the Treatment With Enoxaparin in ACS Admitted to the Emergency. Randomized Clinical Trial ENOXA ® Versus LOVENOX ®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Les Laboratoires des Médicaments Stériles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Les Laboratoires des Médicaments Stériles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical trial monocentric, open, randomized ENOXA ® versus LOVENOX ®,
      conducted on two parallel groups of patients admitted in emergency for acute coronary
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients included in this study with an acute coronary Syndrome be admitted to the
      emergency room and receive treatment with enoxaparin. Low molecular weight heparin (LMWH)
      treatment in this indication is usually spread over a week. The experience of the study
      intends to focus only on the first injection administered in selected patients.

      Two assays are carried out, including an assessment of the anti-Xa activity initially before
      injection of enoxaparin, and 4 hours after administration of the first syringe.

      Clinical monitoring is intrahospital from the date of hospitalization of patients included
      until emergency exit (transfer to another service, or return home)

      Tolerance assessment (clinical and biological) is performed during follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-Xa activity</measure>
    <time_frame>4 hours</time_frame>
    <description>assay of anti-Xa activity 4 hours after the first injection énoxparine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 7 days</time_frame>
    <description>Tolerance is assessed by the occurrence of adverse events and / or serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Factor X</condition>
  <arm_group>
    <arm_group_label>Enoxa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovenox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENOXA®</intervention_name>
    <description>enoxaparine 100 UI/Kg subcutaneous injection</description>
    <arm_group_label>Enoxa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOVENOX®</intervention_name>
    <description>enoxaparine 100 UI/Kg subcutaneous injection</description>
    <arm_group_label>Lovenox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over the age of 20 years

          -  acute coronary syndrome

          -  Admission to the emergency department

        Exclusion Criteria:

          -  Patient participating in another study

          -  Pregnant or lactating or of childbearing potential not using medically accepted method
             of contraception

          -  Taking an anticoagulant in the last three months

          -  Patient with known haemostatic disorder

          -  Contraindication absolute and / or relative to the use of enoxaparin

          -  Nobody wishing to participate in this study or not having the ability to understand
             its objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Semir Nouira, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Fattouma Bourguiba Hospital, Monastir</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohsen Hassine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fattouma Bourguiba, Monastir</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement of Emergency</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>http://www.omicsonline.org/bioequivalence-bioavailability-abstract.php?abstract_id=56339</url>
    <description>abstract link posted on the journal's website</description>
  </link>
  <link>
    <url>http://www.omicsonline.org/open-access/generic-and-branded-enoxaparin-bioequivalence-a-clinical-andexperimental-study-jbb-1000244.pdf</url>
    <description>PDF full text of article published on Journal of Bioequivalence &amp; Bioavailability (open access)</description>
  </link>
  <reference>
    <citation>Boubaker H MD, Grissa MH MD, Sassi M MD, Chakroun T MD, Beltaief K MD, et al. (2015) Generic and Branded Enoxaparin Bioequivalence: A Clinical and Experimental Study. J Bioequiv Availab 7: 225-228. doi:10.4172/jbb.1000244</citation>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2012</study_first_submitted>
  <study_first_submitted_qc>September 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2012</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enoxaparin</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Factor X</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

